Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

Inclusion Criteria: * Voluntary signing of informed consent form; * Liver and kidney function: Blood bilirubin ≤ 35 μ mol/L, AST/ALT \< 2 times the upper limit of normal, blood creatinine ≤ 150 μ mol/L; * Normal heart function (EF ≥ 50%, NYHA I/II); * Physical condition score 0-2 (ECOG score); * Non pregnant and lactating women. For all women of childbearing age, a pregnancy test must be conducted to determine hCG levels in order to exclude pregnancy status; * For all men of childbearing age, contraceptive measures must be taken during sorafenib treatment until 3 months after discontinuation. Exclusion Criteria: * Acute promyelocytic leukemia; * Hematological non-remisssion or recurrence; * Uncontrolled infection or grade 3-4 graft-versus-host disease (GVHD); * Allergies or contraindications to any of the drugs involved in the protocol; * Severe organ dysfunction such as heart, liver, kidneys, lungs, etc.